Pharma
22 articles tagged pharma
Policy Pulse - Modi / India Govt - 13 Oct 2026
PM Modi told the Bloomberg New Economy Forum on October 13 that the routes of globalisation have become chokepoints, naming supply chains, energy, critical minerals and payments, a framing that maps to TCS, INFY, SUNPHARMA and HINDCOPPER. The PMO named no company, so every mapping is inferred.
Policy Pulse - Ministries & Regulators - 09 Oct 2026
The RBI raised daily CRR maintenance to 99% and lined up Rs 25,000 crore of bond sales, negative for rate-sensitive NBFCs and bond-funded lenders; SEBI mandated a colour-coded credit risk-o-meter, positive for CRISIL and ICRA; and a 30% cap on cancer-drug trade margins lifted Apollo Hospitals and Fortis while TCS led a 3% Nifty IT rally.
Policy Pulse - Modi / India Govt - 05 Oct 2026
PM Modi and Swiss President Guy Parmelin signed five agreements at Hyderabad House on Monday, pairing expanded market access for Indian agriculture, pharma, textiles and engineering goods with a $100 billion EFTA investment target and fresh channels in biotech, life sciences, banking and insurance - a positive read-through for SUNPHARMA, WELSPUNLIV and NESTLEIND - alongside a Migration and Mobility Partnership and a Young Professionals Agreement. The PMO named no company, so every mapping here is inferred and confidence-marked. Forward catalyst: Chennai Metro Phase II's first 14 km on October 11.
Policy Pulse - Global Spillover - 30 Sep 2026
The G20 Trade Ministerial opened in Milwaukee on steel excess capacity, MFN erosion and forced labour - the same ground as the Section 301 tariffs under challenge at the Court of International Trade - while core PCE at 3.0% cut October Fed hike odds from 71% to 35% and eased the front end. Saudi Arabia restarted the East-West pipeline and Yanbu loadings, Gulf exports recovered to 23.3 mbpd with Brent near $103, and India kept 0% Section 232 tariffs on specialty drugs, supporting SUNPHARMA and DRREDDY.
Policy Pulse — Ministries & Regulators — 26 Aug 2026
RBI MPC holds repo at 5.25% with GDP raised to 6.7%; Piyush Goyal to visit US for G20 trade meet and USTR talks
Policy Pulse — Ministries & Regulators — 11 Aug 2026
Crude near 90 clouds Sensex (-0.49%) but pharma/IT/refineries shine (Gland +9.6% on Q1 beat, CPCL +14.9%); 'IPOgust' 11 mainboard IPOs raise 21272 cr, lifting BSE/brokers; Shiprocket IPO opens Aug 12
Policy Pulse — Global — 31 Jul 2026
US pharma Section 232 tariffs live (branded protected, generics exempt). India Samudra Manthan energy-security capex (ONGC, OIL). Markets stabilize post-Fed.
Policy Pulse — Ministries & Regulators — 31 Jul 2026
India-US pharma deal exempts Indian generics from Section 232 (BUY SUNPHARMA, DRREDDY, CIPLA). SEBI Stock Brokers Regulations 2026. Nifty Pharma +0.7%.
Policy Pulse — Trump/US — 31 Jul 2026
US Pharmaceutical Section 232 tariffs take effect today: 100% on branded patented drugs, generics exempt. Structural BUY for LLY, MRK, JNJ, PFE, ABBV. Watch Sept 29 expansion.
Policy Pulse — Ministries & Regulators — 30 Jul 2026
Q1 earnings heavy day: Vedanta +152% PAT, Bajaj Finance +29%, Tata Steel +19%. Nifty Auto +1.63% leads markets. GRSE ₹1,032 Cr order. NLC India 900 MW solar win. FIIs net buyers at ₹2,982 Cr.
Policy Pulse — Global Spillover — 24 Jul 2026
Strait of Hormuz crisis at peak — 13th night of US strikes, Iran rejects ceasefire, oil above 00. Generic drug tariff timeline begins Aug 1. Section 122 expiry relief for importers. Stock impact: BUY oil/gas/defence/renewables, SELL airlines/refiners/generic pharma.
Policy Pulse — Modi/Govt — 24 Jul 2026
Cabinet approves ₹3,030 cr BHAVYA Rasayan chemical parks scheme + ₹1,264 cr rail project. India secures lower 10% US tariff under Section 301. Stock impact: BUY chemicals/infra/pharma, SELL steel (US export).
Policy Pulse — Trump/US — 24 Jul 2026
Section 122 expires, replaced by Section 301 (10-12.5%) forced labor tariffs on 60 economies. Iran tariff EO signed. Hormuz crisis deepens — oil above $100. Generic drug tariff timeline begins. Stock impact: BUY oil/defence/retail, SELL airlines/cruises/generic pharma.
Policy Pulse — Global Spillover — 23 Jul 2026
INFY Q1: +12% PAT, guidance trimmed, ADR -4.85%. INDIGO: ₹238cr net loss on fuel costs (85% rise). CIPLA: -39% PAT. Hormuz: 12th night, Brent near 8. IOC/MRPL halt Iraq loadings. Section 122 expiry tomorrow benefits Indian IT/Textiles. ONGC gains, refiners bleed.
Policy Pulse — Trump/US Watch — 23 Jul 2026
Section 122 tariff expires TOMORROW (Jul 24) — USTR missed replacement deadline, Wyden bill to repeal. Hormuz 12th night, Brent near 8. Generic drug tariff structural overhang continues. US retailers (WMT, TGT, COST, AMZN) biggest beneficiaries of Section 122 expiry.
Policy Pulse — Global Spillover — 22 Jul 2026
US-Iran war enters 11th night of strikes; Trump threatens Iranian infrastructure. Hormuz closed — oil 5+, ONGC/OCD gain, refiners bleed. Trump generic drug tariff timeline hits TEVA, MYL globally. US-Jordan trade deal signed. Genesis B AI-for-science unveiled.
Policy Pulse — Modi / India — 22 Jul 2026
Nifty below 24,000 on Brent 5, IOCs halt Iraq oil loadings due to Hormuz (ONGC gains, IOC/BPCL/HPCL pressured). Trump generic drug tariff crushes Sun Pharma, Lupin, Cipla. Nestlé, Bajaj Auto shine on stellar Q1. Bandhan Bank -19% on RoA cut.
Policy Pulse — Trump/US Watch — 22 Jul 2026
Trump escalates Hormuz (threatens Iranian infrastructure), announces generic drug tariff timeline (0%→100%→200%), unveils B Genesis AI Mission. Oil, defence, branded pharma gain; airlines, generic pharma under pressure.
Policy Pulse — Ministries — 20 Jul 2026
📉 Indian markets: Nifty -0.39% amid Iran tension. PSU banks rally on Q1 beats (PNB +5.7%, Union Bank +4.4%). Private banks tank (Axis -5.4%, HDFC -5.1%). Pharma defensive rotation +1%. Space sector boost from Skyroot launch. RBI capital norms still pressuring NSE/BSE/brokerages.
Policy Pulse — Trump — 15 Jul 2026
Trump primetime address July 16 + Section 122 tariff expiry July 24 + pharma onshoring deadline July 31 create 9-day policy window — XOM, LLY, BA positioned for key outcomes.
Policy Pulse — Modi — 13 Jul 2026
India rejects rushed US trade deal — demands tariff edge over China. Risk of steeper tariffs later this month. IT (TCS, INFY) and textiles (WELSPUN, TRIDENT) exposed. HAL receives 7th GE engine — Tejas Mk1A programme gains momentum.
Policy Pulse — Global Trade — 06 Jul 2026
USTR forced labor tariff hearings Jul 7-9 propose 12.5% duty on 60 economies including India; US pharma tariffs (100% on patented) exclude generics — Neutral for Indian API exporters; USMCA not renewed; Brazil tariff deadline Jul 15. Stocks: SUNPHARMA, DRREDDY, DIVIS, TCS, INFY, TATASTEEL, WELSPUN, RAYMOND.